Desferal is going off patent soon and I believe that Cipla, the company that makes Kelfer despite the threats from Ciba-Geigy (now Novartis), is planning to launch a generic version of the drug soon. That should make it available at a far cheaper rate and without shortages. I will see if anyone at Cipla can give me an update.
Also, I believe that Cipla is planning to launch a generic version of Exjade in India - however, given the changed patent laws in India, they are looking at as to what rules they can use to do this. Getting the govt of India to say that Exjade is a life saving drug, and compulsory licencing is required is one such step. Keeping a close tab on this front ....
Novartis is such a jerk of a company - they gave us a presentation about how they are launching Exjade (called Asunra in India) at a different price compared to the rest of the world, and it is still 3-4x more expensive than an equivalent dose of Kelfer. And, going by their documents, it seems like Exjade has a lower chelating power per gram, compared with Kelfer.
I hope Cipla comes through with their version soon.
Poirot